Display options
Cite
Lei T, Xu XL, Chen W, et al. Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer. Onco Targets Ther. 2016;9:921-8doi: 10.2147/OTT.S95517.
Lei, T., Xu, X. L., Chen, W., Xu, Y. P., & Mao, W. M. (2016). Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer. OncoTargets and therapy, 9921-8. https://doi.org/10.2147/OTT.S95517
Lei, Tao, et al. "Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer." OncoTargets and therapy vol. 9 (2016): 921-8. doi: https://doi.org/10.2147/OTT.S95517
Lei T, Xu XL, Chen W, Xu YP, Mao WM. Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer. Onco Targets Ther. 2016 Feb 24;9:921-8. doi: 10.2147/OTT.S95517. eCollection 2016. PMID: 26966380; PMCID: PMC4771404.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2016 Feb 24;9:921-8. doi: 10.2147/OTT.S95517. eCollection 2016.

Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer.

OncoTargets and therapy

Tao Lei, Xiao-Ling Xu, Wei Chen, Ya-Ping Xu, Wei-Min Mao

Affiliations

  1. Department of Medical Oncology, Zhejiang Cancer Hospital, People's Republic of China; Department of Medical Oncology, Zhejiang Cancer Hospital, People's Republic of China.
  2. Key Laboratory of Diagnosis and Treatment Technology for Thoracic Cancer, Zhejiang Cancer Research Institute, People's Republic of China.
  3. Department of Radiotherapy, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, Hangzhou, People's Republic of China.

PMID: 26966380 PMCID: PMC4771404 DOI: 10.2147/OTT.S95517

Abstract

The use of additional radiotherapy for resected stage IIIA N2 non-small-cell lung cancer in the setting of standard adjuvant chemotherapy remains controversial. A comprehensive search (last search updated in March 2015) for relevant studies comparing patients with stage IIIA N2 non-small-cell lung cancer undergoing resection after treatment with adjuvant postoperative chemotherapy alone or adjuvant postoperative chemoradiotherapy (POCRT) was conducted. Hazard ratios (HRs) were extracted from these studies to give pooled estimates of the effects of POCRT on overall survival (OS) and disease-free survival (DFS). Six studies were included. The meta-analysis demonstrated that POCRT had a greater OS benefit than postoperative chemotherapy (HR =0.87, 95% confidence interval [CI]: 0.79-0.96, P=0.006). Unfortunately, there was no significant difference in DFS between the two groups: the combined HR for DFS was 0.91 (95% CI: 0.57-1.46, P=0.706). In a subgroup analysis of two randomized controlled trials (n=172 patients), adding radiation was of no benefit to either OS (HR =0.72, 95% CI: 0.49-1.06, P=0.094) or DFS (HR =1.45, 95% CI: 1.00-2.09, P=0.047). In summary, compared with postoperative chemotherapy, POCRT was beneficial to OS but not DFS in patients with stage IIIA N2 non-small-cell lung cancer.

Keywords: N2-stage; NSCLC; surgery; therapy

References

  1. Trials. 2007 Jun 07;8:16 - PubMed
  2. ANZ J Surg. 2003 Sep;73(9):712-6 - PubMed
  3. J Natl Compr Canc Netw. 2010 Jul;8(7):740-801 - PubMed
  4. J Clin Oncol. 2005 Sep 1;23(25):5883-91 - PubMed
  5. Biometrics. 1994 Dec;50(4):1088-101 - PubMed
  6. J Thorac Oncol. 2007 Aug;2(8):706-14 - PubMed
  7. Br J Radiol. 2004 Jan;77(913):43-8 - PubMed
  8. J Surg Oncol. 1994 Aug;56(4):236-41 - PubMed
  9. Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):321-8 - PubMed
  10. Lung Cancer. 2014 May;84(2):156-60 - PubMed
  11. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  12. J Clin Oncol. 2015 Mar 10;33(8):870-6 - PubMed
  13. J Thorac Oncol. 2015 Jan;10(1):148-55 - PubMed
  14. Lung Cancer. 2005 Nov;50(2):227-34 - PubMed
  15. Semin Oncol. 1997 Aug;24(4):429-39 - PubMed
  16. Cancer. 2012 Sep 15;118(18):4478-85 - PubMed
  17. Clin Lung Cancer. 2014 Sep;15(5):356-64 - PubMed
  18. Lancet Oncol. 2006 Sep;7(9):719-27 - PubMed
  19. J Clin Oncol. 2000 Aug;18(16):2981-9 - PubMed
  20. Radiother Oncol. 2014 Jan;110(1):120-5 - PubMed
  21. Clin Lung Cancer. 2007 Jan;8(4):268-72 - PubMed
  22. Chest. 1997 Jun;111(6):1710-7 - PubMed
  23. Lung Cancer. 2003 Dec;42 Suppl 1:S9-14 - PubMed
  24. J Thorac Oncol. 2011 Jul;6(7):1229-35 - PubMed
  25. N Engl J Med. 1990 Oct 4;323(14):940-5 - PubMed
  26. Open Med. 2009;3(3):e123-30 - PubMed
  27. Oncologist. 2011;16(5):641-50 - PubMed
  28. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
  29. J Thorac Oncol. 2007 Aug;2(8):694-705 - PubMed
  30. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  31. J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5 - PubMed
  32. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):695-701 - PubMed
  33. N Engl J Med. 2004 Jan 22;350(4):351-60 - PubMed

Publication Types